Topical use of Levofloxacin for reducing lung inflammation
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/536
C07D-498/14
출원번호
US-0574666
(2009-10-06)
등록번호
US-8629139
(2014-01-14)
발명자
/ 주소
Dudley, Michael N.
Tsivkovski, Ruslan Y.
Griffith, David C.
Rodny, Olga
출원인 / 주소
MPEX Pharmaceuticals, Inc.
대리인 / 주소
Knobbe, Martens, Olson & Bear, LLP
인용정보
피인용 횟수 :
5인용 특허 :
149
초록
The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided.
대표청구항▼
1. A method for treating a pulmonary inflammation in the absence of a pulmonary bacterial infection in a subject comprising administering to said subject in need thereof an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation, wherein the solution comprises a
1. A method for treating a pulmonary inflammation in the absence of a pulmonary bacterial infection in a subject comprising administering to said subject in need thereof an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation, wherein the solution comprises a divalent or trivalent cation concentration from about 150 mM to about 250 mM, and a levofloxacin or ofloxacin concentration from about 90 mg/ml to about 125 mg/ml. 2. The method of claim 1, wherein the subject has a disorder selected from the group consisting of asthma, cystic fibrosis (CF), pulmonary fibrosis, chronic bronchitis (CB), bronchiectasis, chronic granulomatous disease, sinusitis, chronic obstructive pulmonary disease (COPD), and pneumonia. 3. The method of claim 1, wherein the solution consists essentially of levofloxacin or ofloxacin and the divalent or trivalent cation. 4. The method of claim 1, wherein the solution comprises chloride. 5. The method of claim 1, wherein the solution comprises no lactose. 6. The method of claim 1, wherein the solution has an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg, and a pH from about 5 to about 8. 7. The method of claim 1, wherein the solution has an osmolality from about 350 mOsmol/kg to about 425 mOsmol/kg, and a pH from about 5 to about 6.5. 8. The method of claim 1, wherein the solution has a pH from about 5.5 to about 6.5. 9. The method of claim 1, wherein the divalent or trivalent cation is selected from magnesium, calcium, zinc, copper, aluminum, and iron. 10. The method of claim 1, wherein the solution comprises magnesium chloride. 11. The method of claim 1, wherein the solution has a levofloxacin or ofloxacin concentration from about 90 mg/ml to about 110 mg/ml, a magnesium chloride concentration between about 175 mM to about 225 mM, a pH between about 5 to about 7; an osmolarity of from about 300 mOsmol/kg to about 500 mOsmol/kg, and lacks lactose. 12. The method of claim 1, wherein the aerosol comprises a mass median aerodynamic diameter from about 2 microns to about 5 microns with a geometric standard deviation less than or equal to about 2.5 microns. 13. The method of claim 1, wherein the aerosol comprises a mass median aerodynamic diameter from about 2.5 microns to about 4.5 microns with a geometric standard deviation less than or equal to about 1.8 microns. 14. The method of claim 1, wherein the aerosol comprises a mass median aerodynamic diameter from about 2.8 microns to about 4.3 microns with a geometric standard deviation less than or equal to about 2 microns. 15. The method of claim 1, comprising producing the aerosol with a vibrating mesh nebulizer. 16. The method of claim 15, wherein the vibrating mesh nebulizer is a PARI E-FLOW® nebulizer. 17. The method of claim 1, wherein at least about 20 mg of levofloxacin or ofloxacin is administered to the lung. 18. The method of claim 1, wherein at least about 100 mg of levofloxacin or ofloxacin is administered to the lung. 19. The method of claim 1, wherein at least about 125 mg of levofloxacin or ofloxacin is administered to the lung. 20. The method of claim 1, wherein at least about 150 mg of levofloxacin or ofloxacin is administered to the lung. 21. The method of claim 1, wherein the aerosol is administered to the lung in less than about 10 minutes. 22. The method of claim 1, wherein the aerosol is administered to the lung in less than about 5 minutes. 23. The method of claim 1, wherein the aerosol is administered to the lung in less than about 3 minutes. 24. The method of claim 1, wherein the aerosol is administered to the lung in less than about 2 minutes. 25. The method of claim 1, comprising administering the aerosol once daily. 26. The method of claim 1, comprising administering the aerosol twice daily. 27. The method of claim 1, further comprising co-administering an additional active agent selected from the group consisting of anti-inflammatory agent, antibiotic, bronchodilator, anticholinergic, glucocorticoid, eicosanoid inhibitor, and combinations thereof. 28. The method of claim 27, wherein co-administering comprises inhaling the additional active agent. 29. The method of claim 27, wherein the antibiotic is selected from the group consisting of tobramycin, aztreonam, ciprofloxacin, azithromycin, erythromycin tetracycline, quinupristin, linezolid, vancomycin, and chloramphenicol, colisitin and combinations thereof. 30. The method of claim 27, wherein the bronchodilator is selected from the group consisting of salbutamol, levosalbuterol, terbutaline, fenoterol, terbutlaine, pirbuterol, procaterol, bitolterol, rimiterol, carbuterol, tulobuterol, reproterol, salmeterol, formoterol, arformoterol, bambuterol, clenbuterol, indacterol, theophylline, roflumilast, cilomilast, and combinations thereof. 31. The method of claim 27, wherein the anticholinergic is selected from the group consisting of ipratropium, tiotropium, and combinations thereof. 32. The method of claim 27, wherein the glucocorticoid is selected from the group consisting of prednisone, fluticasone, budesonide, mometasone, ciclesonide, beclomethasone, and combinations thereof. 33. The method of claim 27, wherein the eicosanoid inhibitor is selected from the group consisting of montelukast, pranlukast, zafirlukast, zileuton, ramatroban, seratrodast, and combinations thereof. 34. A method for treating a pulmonary inflammation in the absence of a pulmonary bacterial infection in a subject, wherein the pulmonary inflammation is induced by one or more pro-inflammatory cytokines, said method comprising administering to said subject in need thereof an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation to achieve a reduction in the pulmonary concentration of said cytokine by at least 10%, wherein the solution comprises a divalent or trivalent cation concentration from about 150 mM to about 250 mM, and a levofloxacin or ofloxacin concentration from about 90 mg/ml to about 125 mg/ml. 35. The method of claim 34, wherein the pulmonary concentration of said cytokine is reduced by at least 20%. 36. The method of claim 34, wherein the pulmonary concentration of said cytokine is reduced by at least 40%. 37. The method of claim 34, wherein the pulmonary concentration of said cytokine is reduced by at least 60%. 38. The method of claim 34, wherein the pulmonary concentration of said cytokine is reduced by at least 80%. 39. A method for treating a pulmonary inflammation in the absence of a pulmonary bacterial infection in a subject comprising administering to said subject in need thereof an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation to achieve a reduction in the pulmonary concentration of one or more pro-inflammatory cytokines selected from IL-1β, IL-6 and IL-8, whereby the pulmonary inflammation is reduced or suppressed, wherein the solution comprises a divalent or trivalent cation concentration from about 150 mM to about 250 mM, and a levofloxacin or ofloxacin concentration from about 90 mg/ml to about 125 mg/ml. 40. The method of claim 39, wherein the cytokine comprises IL-1β. 41. The method of claim 39, wherein the cytokine comprises IL-6. 42. The method of claim 39, wherein the cytokine comprises IL-8. 43. A method for treating a pulmonary inflammation in the absence of a pulmonary bacterial infection in a subject, wherein the pulmonary inflammation is induced by one or more mediators selected from TNFα and LPS, said method comprising administering to said subject in need thereof an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation, wherein the solution comprises a divalent or trivalent cation concentration from about 150 mM to about 250 mM, and a levofloxacin or ofloxacin concentration from about 90 mg/ml to about 125 mg/ml. 44. A method for reducing the pulmonary concentration of one or more pro-inflammatory cytokine in the absence of a pulmonary bacterial infection in a subject, said method comprising administering to said subject in need thereof an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation, wherein the solution comprises a divalent or trivalent cation concentration from about 150 mM to about 250 mM, and a levofloxacin or ofloxacin concentration from about 90 mg/ml to about 125 mg/ml. 45. The method of claim 44, wherein the cytokine comprises IL-1β. 46. The method of claim 44, wherein the cytokine comprises IL-6. 47. The method of claim 44, wherein the cytokine comprises IL-8.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (149)
Schmidt, James N.; Engelbreth, Daniel; Blacker, Rick, Aerosol delivery apparatus with positive expiratory pressure capacity.
James N. Schmidt CA; Jerry Grychowski ; Daniel K. Engelbreth CA; Robert Morton CA; Martin P. Foley CA, Aerosol medication delivery apparatus and system.
Osbakken, Robert S.; Hale, Mary Anne; Leivo, Frederick T.; Munk, James D., Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis.
Gordeev, Mikhail F.; Patel, Dinesh V.; Barbachyn, Michael R.; Gage, James R., Antimicrobial quinolone derivatives and use of the same to treat bacterial infections.
Gordeev, Mikhail F.; Patel, Dinesh V.; Barbachyn, Michael R.; Gage, James R., Antimicrobial quinolone derivatives and use of the same to treat bacterial infections.
Hodson Peter D. (Trowell GB3) Baum Eric A. (Loughborough GB3) Smith David K. (Loughborough GB3) Kuepper Anton (Kaarst DEX) Wilby Matthew J. (Loughborough GB3), Breath actuated inhaler having an electromechanical priming mechanism.
Newell Robert E. (Pinner GB2) Rand Paul K. (Nitchin GB2) Fitzsimmons Robert A. (Barnard Castle GB2), Devices for administering medicaments to patients.
Casper, Robert A.; Leith, Frank A.; Gardner, David L.; Snow, John M.; Lyon, Zachary W.; Farrar, David S., Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament.
Mulhauser Paul (New York NY) Karg Jeffrey (Waldwick NY) Foxen Thomas (Brooklyn NY) Brooks Christopher J. (Glen Head NY), Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same.
Domagala John M. (Canton MI) Kiely John S. (Ann Arbor MI) Schroeder Mel C. (Dexter MI), Individual stereosiomers of 7-[3-(aminoalkyl)-1-pyrrolidinyl]-quinolones and naphthyridones as antibacterial agents.
Burns James S. (Darien CT) Marshak Daniel R. (Cold Spring Harbor NY), Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means.
Ambrosio Thomas J. ; Ashley Charles R. ; Bilanin Alan J. ; Huck Charles M. ; Kaufman Andrew E. ; Kenyon David J. ; Manthena Srinivas ; Sochon Henry R. ; Wilkinson Ken ; Yang Tsong-Toh, Inhaler for powdered medications.
Hess Joseph,CHX ; Bo Hu,CHX ; Weber Raphael,CHX ; Ortega Isabel,CHX ; Barraud Cedric,CHX ; van der Schoot Bart,CHX ; de Rooij Nicolaas Frans,CHX ; de Heij Bas,CHX, Liquid droplet spray device for an inhaler suitable for respiratory therapies.
Zoltan Bart J. (Old Tappan NJ) Laube Beth L. (Baltimore MD) Adams ; III George K. (Baltimore MD) Bow Clark F. (Newton NJ) Devito Ralph J. (Stanhope NJ) Harrington Walter (Flanders NJ) Hoffman Louis S, Medication delivery system phase two.
Smith Adrian E. ; Burr John D. ; Etter Jeffery W. ; Axford George S. ; Lyons Shirley W. ; Platz Robert M., Method and apparatus for dispersion of dry powder medicaments.
Blineau Joseph (Rennes FRX) Pommier Daniel (Mordelles FRX) Thomas Claude (Chasne sur Illet FRX), Multiplex channels for continuous flow for numerical signal.
Nowacki Christopher (Arlington Heights IL) Brisson Alfred G. (Kildeer IL) Dela-Cruz Exequiel (Arlington Heights IL), Pediatric asthmatic medication inhaler.
Arnold Klaus (Ingelheim am Rhein DEX) Grass Peter (Ingelheim am Rhein DEX) Knecht Adolf (Freiburg DEX) Roos Robert (Ingelheim am Rhein DEX) Sluke Gerhard (Ingelheim am Rhein DEX) Thieme Herbet (Ingel, Powders for inhalation.
Knight Jack V. (Houston TX) Wilson ; Jr. Samuel Z. (Houston TX), Small particle aerosol generator for treatment of respiratory disease including the lungs.
Welsh, Michael J.; Zabner, Joseph, Use of xylitol to reduce ionic strength and activate endogenous antimicrobials for prevention and treatment of infections.
Griffith, David C.; Dudley, Michael N.; Surber, Mark W.; Bostian, Keith A.; Rodny, Olga, Aerosol fluoroquinolone formulations for improved pharmacokinetics.
Griffith, David C.; Dudley, Michael N.; Surber, Mark W.; Bostian, Keith A.; Rodny, Olga, Aerosol fluoroquinolone formulations for improved pharmacokinetics.
Griffith, David C.; Dudley, Michael N.; Surber, Mark W.; Bostian, Keith A.; Rodny, Olga, Aerosol fluoroquinolone formulations for improved pharmacokinetics.
Loutit, Jeffery S.; Morgan, Elizabeth E.; Dudley, Michael N.; Griffith, David C.; Lomovskaya, Olga, Use of aerosolized levofloxacin for treating cystic fibrosis.
Loutit, Jeffery S.; Morgan, Elizabeth E.; Dudley, Michael N.; Griffith, David C.; Lomovskaya, Olga, Use of aerosolized levofloxacin for treating cystic fibrosis.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.